Related Experiment Video
Updated: May 26, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
Published on: June 11, 2020
Glycyrrhizin administration ameliorates coxsackievirus B3-induced myocarditis in mice
Haichen Zhang1, Yunxiao Song, Zhichuan Zhang
1Department of Clinical Laboratory, Shanghai Xuhui Central Hospital, China.
Abstract:
In this study, the authors explored the therapeutic effect of glycyrrhizin (GL) on Coxsackievirus B3 (CVB3)-induced myocarditis and its possible mechanisms involved. The results of this study showed that GL exhibited a profound amelioration of CVB3-induced myocarditis, as evidenced by improved weight loss profile, less increased serological levels of cardiac enzymes, less myocardial inflammation and increased survival rate. Further study showed that this effect was not due to the viral clearance but ascribed to weakened proinflammatory responses, as evidenced by significantly reduced expression of proinflammatory cytokines, including tumor necrosis factor-α, interleukin-1β and interleukin-6. Moreover, the authors demonstrated that GL administration inhibited CVB3-induced nuclear factor-κB activity efficiently by blocking the degradation of nuclear factor -κB inhibitor IκBκ. These data suggest that GL can effectively attenuate the severity of CVB3-induced myocarditis and may present as a new therapeutic approach for the treatment of viral myocarditis.
Related Concept Videos
Myocarditis III: Medical Management
Myocarditis I: Introduction
Myocarditis IV: Nursing Management
Endocarditis III: Medical Management
